Certificate under Regulation 74(5) of SEBI (DP) Regulation 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has submitted a routine quarterly compliance certificate under SEBI's Regulation 74(5) for the quarter ended 31 March 2025. The certificate was issued by the company's Registrar and Share Transfer Agent, MUFG Intime India Pvt Ltd, confirming that all securities received for dematerialization during the quarter were properly processed, listed on stock exchanges, and that physical share certificates were cancelled after verification with depository names updated in the register of members. The same disclosure was filed separately with BSE, CDSL, and NSDL on 5 April 2025. No financial numbers, business update, or material event is mentioned in this filing.
No impact on shareholders or the stock price — this is a standard procedural compliance filing that simply confirms the proper handling of share dematerialization requests for the quarter.